title: Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial.
abstract: In managing patients with bleeding peptic ulcers, it has been reported that pharmacologic treatment can be an alternative to endoscopic treatment. We compared the hemostasis rates of the endoscopic treatment, hemoclipping, and the pharmacologic treatment, oral proton pump inhibitors (PPIs), in bleeding peptic ulcer. A randomized prospective study was performed on 129 bleeding peptic ulcer patients with hematemesis or melena. Sixty-two patients were treated by endoscopic hemoclipping and subsequently H(2) receptor antagonists were injected intravenously (hemoclipping group), and 67 patients were treated with an oral PPI without endoscopic treatment (PPI group). The 24-hr gastric pH test was performed sequentially following the treatment. The initial hemostasis rate of the hemoclipping group was 93.5% (58/62) and the rebleeding rate was 6.9% (4/58), and the hemostasis rate of the PPI group was 92.5% (62/67) and the rebleeding rate was 7.5% (5/67), which were not different. The 24-hr gastric pH was 4.54+/-2.56 in the hemoclipping group and 5.97+/-1.30 in the PPI group (P<0.037). In the bleeding peptic ulcer patients, the hemostasis rate with the oral administration of PPIs was not different from that with the endoscopic hemoclipping treatment.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, The Catholic University of Korea, Korea.
authors.forename: Jin Ii
authors.initials: JI
authors.lastname: Kim
authors.forename: Dae Young
authors.initials: DY
authors.lastname: Cheung
authors.forename: Se Hyun
authors.initials: SH
authors.lastname: Cho
authors.forename: Soo-Heon
authors.initials: SH
authors.lastname: Park
authors.forename: Joon-Yeol
authors.initials: JY
authors.lastname: Han
authors.forename: Jae Kwang
authors.initials: JK
authors.lastname: Kim
authors.forename: Sok Won
authors.initials: SW
authors.lastname: Han
authors.forename: Kyu Yong
authors.initials: KY
authors.lastname: Choi
authors.forename: In Sik
authors.initials: IS
authors.lastname: Chung
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004381:Duodenal Ulcer; D016099:Endoscopy, Gastrointestinal / Q000379:methods; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D016558:Hemostasis, Endoscopic / Q000295:instrumentation*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010438:Peptic Ulcer Hemorrhage / Q000628:therapy*; D011446:Prospective Studies; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors*; D064750:Rabeprazole; D012008:Recurrence; D013276:Stomach Ulcer; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D064750:Rabeprazole; D006180:Proton-Translocating ATPases